Castañeda C - Search Results

1

The implementation of the Plan Esperanza and response to the imPACT Review.

Vidaurre T, Santos C, Gómez H, Sarria G, Amorin E, López M, Regalado R, Manrique J, Tarco D, Ayestas C, Calderón M, Mas L, Neciosup S, Salazar M, Chávez JC, Ubillus M, Limache A, Ubillus JC, Navarro J, Sarwal K, Sutcliffe S, Gutiérrez-Aguado A, Silva M, Mena A, Guillén ME, Castañeda C, Abugattas J. Vidaurre T, et al. Among authors: castaneda c. Lancet Oncol. 2017 Oct;18(10):e595-e606. doi: 10.1016/S1470-2045(17)30598-3. Lancet Oncol. 2017. PMID: 28971826 Review.

2

Targeted therapies: Combined lapatinib and paclitaxel in HER2-positive breast cancer.

Castañeda CA, Gomez HL. Castañeda CA, et al. Nat Rev Clin Oncol. 2009 Jun;6(6):308-9. doi: 10.1038/nrclinonc.2009.68. Nat Rev Clin Oncol. 2009. PMID: 19483734

3

Pazopanib: an antiangiogenic drug in perspective.

Castaneda CA, Gomez HL. Castaneda CA, et al. Future Oncol. 2009 Nov;5(9):1335-48. doi: 10.2217/fon.09.112. Future Oncol. 2009. PMID: 19903063 Review.

4

Prolonged disease control in a patient with anthracycline- and taxane-resistant breast cancer.

Castaneda CA, Gómez HL. Castaneda CA, et al. Clin Breast Cancer. 2009 Nov;9(4):E1-3. doi: 10.3816/CBC.2009.n.046. Clin Breast Cancer. 2009. PMID: 19933071

5

Prognostic effect of hormone receptor status in early HER2 positive breast cancer patients.

Gómez HL, Castañeda CA, Vigil CE, Vidaurre T, Velarde RG, Cruz WR, Pinto JA, Suazo JF, Garcés MR, Neciosup SP, Vallejos CS. Gómez HL, et al. Hematol Oncol Stem Cell Ther. 2010;3(3):109-15. doi: 10.1016/s1658-3876(10)50020-7. Hematol Oncol Stem Cell Ther. 2010. PMID: 20890067 Free article.

6

The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer.

Castaneda CA, Cortes-Funes H, Gomez HL, Ciruelos EM. Castaneda CA, et al. Cancer Metastasis Rev. 2010 Dec;29(4):751-9. doi: 10.1007/s10555-010-9261-0. Cancer Metastasis Rev. 2010. PMID: 20922461 Review.

7

Implication of miRNA in the diagnosis and treatment of breast cancer.

Castañeda CA, Agullo-Ortuño MT, Fresno Vara JA, Cortes-Funes H, Gomez HL, Ciruelos E. Castañeda CA, et al. Expert Rev Anticancer Ther. 2011 Aug;11(8):1265-75. doi: 10.1586/era.11.40. Expert Rev Anticancer Ther. 2011. PMID: 21916580 Review.

8

PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers.

Castaneda CA, Lopez-Ilasaca M, Pinto JA, Chirinos-Arias M, Doimi F, Neciosup SP, Rojas KI, Vidaurre T, Balko JM, Arteaga CL, Gomez HL. Castaneda CA, et al. Hematol Oncol Stem Cell Ther. 2014 Dec;7(4):142-8. doi: 10.1016/j.hemonc.2014.09.007. Epub 2014 Oct 29. Hematol Oncol Stem Cell Ther. 2014. PMID: 25467032 Free article.

9

Prognostic factors for patients with newly diagnosed brain metastasis from breast cancer.

Castaneda CA, Flores R, Rojas KY, Castillo M, Dolores-Cerna K, Flores C, Belmar-Lopez C, Milla E, Gomez H. Castaneda CA, et al. CNS Oncol. 2015;4(3):137-45. doi: 10.2217/cns.15.5. Epub 2015 Apr 23. CNS Oncol. 2015. PMID: 25906174 Free PMC article.

10

Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy.

Castaneda CA, Mittendorf E, Casavilca S, Wu Y, Castillo M, Arboleda P, Nunez T, Guerra H, Barrionuevo C, Dolores-Cerna K, Belmar-Lopez C, Abugattas J, Calderon G, De La Cruz M, Cotrina M, Dunstan J, Gomez HL, Vidaurre T. Castaneda CA, et al. World J Clin Oncol. 2016 Oct 10;7(5):387-394. doi: 10.5306/wjco.v7.i5.387. World J Clin Oncol. 2016. PMID: 27777881 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

313 results

Search Page